Compare CVS Health Corp (CVS) vs HubSpot Inc (HUBS) Price & Performance

CVS Health trades at $95.70, down 0.54% on the day, with a bearish technical signal and key support at $95. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.58 versus $1.87 expected, and raised its full-year guidance. Revenue growth remains robust, reaching $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst sentiment is overwhelmingly positive with a consensus price target of $115.00.

The outlook for CVS is cautiously optimistic, driven by operational improvements in its Aetna segment and raised cash flow guidance. Investment opportunities include potential upside to the consensus target, but risks involve margin pressures, regulatory changes impacting pharmacy benefits in 2027, and high debt levels. The stock's current valuation at a P/E of 25.25 may limit near-term gains if earnings growth slows.

HubSpot (HUBS) trades at $210.35, up 3.91% today, but remains in a bearish technical trend with strong selling pressure on moving averages. The company shows solid revenue growth with Q2 2026 earnings beating estimates at $3.26 EPS, though recent guidance cuts and a securities fraud investigation have created significant volatility. Fundamentals reveal strong gross margins of 83.25% but modest net income margins of 4.26%, with valuation metrics indicating premium pricing at P/E 74.89 and P/S 3.22.

The outlook is mixed with 76.59% analyst buy ratings and a $233.93 consensus target suggesting 11% upside, but near-term risks from customer growth slowdown and legal challenges weigh on sentiment. Long-term AI transformation strategy offers potential, but execution risks and competitive pressures require careful monitoring for investors considering entry at current levels.